Nourhan El Ahmar

Nourhan El Ahmar

Auto-generated profile, based on publicly available information

Nourhan El Ahmar

Brigham and Women’s Hospital 7 Department of Pathology Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2025 in Cancer Discovery
Verified
Journal Article
Closed access
MHMiya B. Hugaboom
Miya B. Hugaboom
LWLena V. Wirth
Lena V. Wirth
KSKelly Street
Kelly Street
NRNeil Ruthen
Neil Ruthen
OJOpeyemi A. Jegede
Opeyemi A. Jegede
DBDavid A. Braun
David A. Braun
Immune checkpoint inhibitors targeting the PD-1 pathway have transformed treatment of advanced renal cell carcinoma (RCC), but mechanisms underlying the therapeutic response remain largely unknown. In this study, we perform transcriptomic analysis on RCC biospecimens from 102 patients enrolled in a phase II clinical trial of first-line nivolumab (NCT03117309) to investigate determinants of response to anti–PD-1 monotherapy. Through bulk analysis, we identify an enrichment of genes associated with tertiary lymphoid structures (TLS) in responding patients. Using single-cell transcriptomics and external cohort validation, we identify a population of tissue-resident (ZNF683+SLAMF7+) exhausted CD8+ T cells enriched in patients with poor clinical outcomes. Integrating these findings, we find tumors with high TLS and low tissue-resident exhausted CD8+ T cells that have superior clinical outcomes with nivolumab. Altogether, these analyses contribute to a growing understanding of how the tumor microenvironment drives immune checkpoint inhibitor resistance and propose possible therapeutic targets to rationally overcome resistance to anti–PD-1 monotherapy. Significance: We describe a paradigm wherein combined high TLS and low tissue-resident exhausted CD8+ T cells are required for optimal response to PD-1 blockade in RCC. This analysis identifies key determinants of response to PD-1 blockade in advanced RCC and suggests avenues for future immune modulation through rational combination therapy strategies.

7 December 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TDThomas Denize
Thomas Denize
OJOpeyemi A. Jegede
Opeyemi A. Jegede
SMSayed Matar
Sayed Matar
NANourhan El Ahmar
Nourhan El Ahmar
DWDestiny J. West
Destiny J. West
SSSabina Signoretti
Sabina Signoretti
Purpose: Programmed cell death protein 1 (PD-1) expression on CD8+TIM-3−LAG-3− tumor-infiltrating cells predicts positive response to PD-1 blockade in metastatic clear-cell renal cell carcinoma (mccRCC). Because inhibition of PD-1 signaling in regulatory T cells (Treg) augments their immunosuppressive function, we hypothesized that PD-1 expression on tumor-infiltrating Tregs would predict resistance to PD-1 inhibitors. Experimental Design: PD-1+ Tregs were phenotyped using multiparametric immunofluorescence in ccRCC tissues from the CheckMate-025 trial (nivolumab: n = 91; everolimus: n = 90). Expression of CD8, PD-1, TIM-3, and LAG-3 was previously determined (Ficial and colleagues, 2021). Clinical endpoints included progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). Results: In the nivolumab (but not everolimus) arm, high percentage of PD-1+ Tregs was associated with shorter PFS (3.19 vs. 5.78 months; P = 0.021), shorter OS (18.1 vs. 27.7 months; P = 0.013) and marginally lower ORR (12.5% vs. 31.3%; P = 0.059). An integrated biomarker (PD-1 Treg/CD8 ratio) was developed by calculating the ratio between percentage of PD-1+Tregs (marker of resistance) and percentage of CD8+PD-1+TIM-3−LAG-3− cells (marker of response). In the nivolumab (but not everolimus) arm, patients with high PD-1 Treg/CD8 ratio experienced shorter PFS (3.48 vs. 9.23 months; P < 0.001), shorter OS (18.14 vs. 38.21 months; P < 0.001), and lower ORR (15.69% vs. 40.00%; P = 0.009). Compared with the individual biomarkers, the PD-1 Treg/CD8 ratio showed improved ability to predict outcomes to nivolumab versus everolimus. Conclusions: PD-1 expression on Tregs is associated with resistance to PD-1 blockade in mccRCC, suggesting that targeting Tregs may synergize with PD-1 inhibition. A model that integrates PD-1 expression on Tregs and CD8+TIM-3−LAG-3− cells has higher predictive value.

19 June 2026 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
PYPei Tung Stephanie Yiu
Pei Tung Stephanie Yiu
YCYuzhou Chang
Yuzhou Chang
YYYao Yu Yeo
Yao Yu Yeo
HQHuaying Qiu
Huaying Qiu
WWWenrui Wu
Wenrui Wu
SJSizun Jiang
Sizun Jiang
Spatial transcriptomics and proteomics have enabled profound insights into tissue organization, yet these technologies remain largely disparate, and emerging same-slide multiomics approaches are limited in plex, spatial resolution, signal retention, and integrative analytics. We introduce IN-situ DEtailed Phenotyping To High-resolution transcriptomics (IN-DEPTH), a streamlined, resource-efficient, commercially compatible workflow using single-cell spatial proteomics-derived imaging to guide transcriptomic capture on the same slide without RNA signal loss. To integrate modalities beyond niche-level mapping, we developed Spectral Graph Cross-Correlation (SGCC), a proteomic–transcriptomic framework resolving spatially coordinated functional state changes across interacting cell populations. Applied to diffuse large B-cell lymphoma (DLBCL), IN-DEPTH and SGCC enabled stepwise discovery from Epstein–Barr virus (EBV)–positive and EBV-negative tumor comparisons with single-cell resolution, revealing coordinated tumor–macrophage–CD4 T-cell remodeling, immunosuppressive C1Q macrophage enrichment, CD4 T-cell dysfunction, and a candidate IL27–STAT3 signaling axis. Collectively, IN-DEPTH enables scalable spatial multiomics to uncover clinically relevant microenvironmental mechanisms and toward robust spatial multimodal AI models. Significance: IN-DEPTH enables same-slide spatial multiomics across commercial platforms via a protein-first strategy preserving protein epitopes, RNA quality, and tissue integrity. Coupled with SGCC, it resolves coordinated spatial immune remodeling, revealing EBV/LMP1-driven C1Q macrophage polarization and CD4 T-cell dysfunction in DLBCL, with broad applicability to other diseases.

12 June 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
NANourhan El Ahmar
Nourhan El Ahmar
MPMorgan A. Paul
Morgan A. Paul
BSBerkay Simsek
Berkay Simsek
SMSayed Matar
Sayed Matar
OJOpeyemi A. Jegede
Opeyemi A. Jegede
SSSabina Signoretti
Sabina Signoretti
Purpose: We investigated components of the immune tumor microenvironment as determinants of clinical outcome to anti–PD-1 therapy in patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with first-line nivolumab in the phase II, nonrandomized HCRN GU16-260 trial. Experimental Design: Pretreatment primary ccRCCs from 72 patients were analyzed via multiplex immunofluorescence and image analysis to assess nonterminally exhausted CD8+ (CD8+PD-1+TIM-3−LAG-3−) tumor-infiltrating lymphocytes (TIL), PD-1+ regulatory T cells (Treg), total and peritumoral tertiary lymphoid structures (TLS), and CD163+ tumor-associated macrophages (TAM). Clinical endpoints included objective response rate (ORR) and progression-free survival (PFS). Results: The densities of CD8+PD-1+TIM-3−LAG-3− TILs, total and peritumoral TLSs, and CD163+ TAMs, as continuous variables, were associated with improved ORR [odds ratio: 1.54 (1.10–2.16) for TILs; 1.18 (1.02–1.37) for total TLSs; 1.10 (1.02–1.18) for peritumoral TLSs; and 2.21 (1.33–3.69) for TAMs] and longer PFS [hazard ratio: 0.79 (0.67–0.95) for TILs; 0.92 (0.85–0.99) for total TLSs; 0.94 (0.90–0.98) for peritumoral TLSs; and 0.77 (0.61–0.97) for TAMs]. Although the percentage of PD-1+ Tregs as a continuous variable was not associated with outcomes, at an optimal cutoff, a high percentage of PD-1+ Tregs tended to be associated with lower ORR (12.5% vs. 43.6%, P = 0.093) and was associated with shorter PFS (3.4 vs. 10.9 months, P < 0.001). The biomarkers were not strongly correlated with each other, and their integration in multibiomarker models further stratified outcomes. Conclusions: Individual immune cell populations within the ccRCC microenvironment are associated with response/resistance to first-line anti–PD-1 therapy. Our findings support the development of combined immune marker models to identify patients with divergent outcomes.